For many years, the importance of preservation injury has been under-recognized in kidney transplantation -delayed graft function (DGF) was seen as a phenomenon with little or no long-term consequences following kidney transplantation. Now, however, an important association is recognized between DGF and poor outcome: there is a higher rate of chronic allograft nephropathy and fi ve-year graft survival is reduced. 1 Concerns over the longer-term eff ects of acute tubular necrosis (the underlying injury in DGF) have been raised further with the increasing use of kidneys from non-heart-beating donors -kidneys that are removed aft er circulatory arrest and therefore undergo an inevitable period of warm ischemia before cold preservation. Th ere is thus now much more interest in kidney preservation than previously.
In this issue, Ahmad et al. present in vivo functional data to demonstrate that immediate renal function after warm ischemic injury is infl uenced by the choice of preservation solution. 2 Th ey used an in vivo model to study protection of the kidney during 45 minutes of normothermic ischemia and 2 hours of reperfusion. PBS140, a simple formulation of readily available and low-cost reagents, 3 proved to be at least as eff ective as, or superior to, the 'gold standard' cold preservation solution, University of Wisconsin (UW) solution, and better than the still widely used Euro-Collins and hyperosmolar citrate solutions.
Th is study builds on previous studies from the same group, both in vitro using an isolated renal proximal tubule preparation 4 and in an in vivo model 5 looking at PBS140 in comparison with more commonly used preservation solutions. Th is work showed that during cold ischemia PBS140 was the most eff ective preservation solution, limiting proximal tubule cell edema during prolonged cold storage and providing maximal protection during subsequent simulated warm ischemia. Taken together, this series of experiments suggests that PBS140 is a good renal preservation solution, resulting in minimal cell edema during cold storage and providing protection during the rewarming phase of transplantation. Now, functional data are presented to support the use of PBS140 during normothermic ischemia -showing that improved protection translates to better functional recovery in the immediate reperfusion phase. It is reasonable to assume that the reduction in ischemia/reperfusion injury aff orded by PBS140 should result in less delayed graft function and, in turn, improved long-term graft survival.
What would it take for a new cold preservation solution to topple UW solution from its position of market dominance? It would need to be either signifi cantly more eff ective or comparably eff ective and signifi cantly cheaper. Although the published evidence suggests that PBS140 may be at least comparable to UW in efficacy, data will be required from a randomized trial before any real shift is likely in what has traditionally been a conservative market. Despite strong evidence from trials in liver transplantation published some time previously, 6 UW solution only became widely used by the renal community following the publication of a large, randomized trial of its use in kidney transplantation. 7 Although kidney preservation is the largest market, it may also be important to demonstrate whether any advantage of PBS140 is unique to kidneys or whether the benefi ts are also seen in all areas of solid organ transplantation. Th e future of PBS140 in extrarenal preservation may, however, be as the basis for a more complex preservation solution. Previous publications from the same group, using isolated rat liver perfusion, have reported a benefi cial eff ect of adding lactobionic acid 8 -this prevented liver weight gain (a marker of cell swelling) during cold storage and allowed greater bile production and lower enzyme rises on reperfusion. Th e addition of 20 mol/l polyethylene glycol to standard PBS140 also caused a signifi cant decrease in weight gain during cold storage and reduced enzymes rises on reperfusion in rat liver transplantation. Polyethylene glycol is thought to off er protection from osmotic cell swelling, reduced lipid peroxidation, and immune modulation. 9 Besides clinical efficacy, the other important potential selling point of a PBS140 is price. PBS140 is based on lowcost components and is theoretically cheap to manufacture -although if the complexity of the solution increases, so too will the cost. However, the commercial aspects are more complex: the selling price of a product refl ects not only the cost of components and manufacture, but also the large investment in development, clinical trials, licensing, and marketing and, fi nally, the size of the market. It is undoubtedly in the interest of the consumer for there to be competition in any market in order to drive down prices; at There is now a resurgence of interest in machine perfusion of kidneys -continuous pumping of cold solution through the kidney. Once a minority interest, this technique is now gaining acceptance because of an increasingly held view that it results in a much lower rate of delayed graft function. 10 Clearly it will be important to compare PBS140 with UW solution in conventional kidney transplantation, but it may become equally relevant to test it against machine perfusion.
The real challenge now lies in the preservation of kidneys from marginal donors. As the demand for transplantation increases and the supply of 'ideal' organs (typically from young, heartbeating donors) decreases, organs are now routinely transplanted from donors that would have been rejected in the past. Th ese include older donors, those with cardiovascular disease, those on large doses of inotropic support, and, particularly, non-heart-beating donors. It is this last group that is increasing rapidly, partly as a result of changing neurosurgical practice. Organs from non-heartbeating donors experience a period of warm ischemia before cold preservation. Th is combination of injuries is associated with a much higher rate of acute tubular necrosis and delayed graft function. Th e results reported by Ahmad et al. in this issue are important not just because these demonstrate the potential of another cold preservation solution, but because the experiments were carried out specifically to investigate preservation during warm ischemia -as seen in the situation of the non-heart-beating donor. It is possible that non-heart-beating donor renal transplantation will prove to be the niche that enables PBS140 to break into the preservation market. Th e immune system in mammals consists of innate and adaptive immunity. The adaptive immune system is a sophisticated system mediated by antigen-specifi c T cells and B cells. Th e innate immune system is phylogenetically conserved and is the fi rst line of host defense against pathogenic microorganisms. Recently, great interest in innate immunity has emerged with the discovery of special germ line-encoded pathogen-pattern recognition receptors called Toll-like receptors (TLRs). It appears that TLRs control activation of adaptive immune responses. 1 To date, 11 human and 9 murine proteins related to the Drosophila Toll gene have been characterized. [1] [2] [3] Th ese receptors specifi cally recognize pathogen-associated molecular patterns that are expressed on or in infectious agents, including lipopolysaccharide, lipoprotein, peptidoglycan, bacterial DNA, and viral double-stranded RNA. [1] [2] [3] Upon ligand binding, TLR-mediated signaling activates signal transduction pathways (such as nuclear factor-κB, c-Jun NH 2 -terminal kinase/p38, nuclear factor/interleukin-6, and interferon regulatory factor) that induce cytokines, chemokines, and increased expression of cellular membrane proteins related to infl ammatory responses. [1] [2] [3] Identifying endogenous ligands has generated evidence that TLR signaling contributes to infl ammation in the absence of microbes. Th ese ligands
